Allarity Therapeutics, Inc.
ALLRNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $320,000 | $0 | — | — | — | — |
| Operating income | −$12.6M | −$27.2M | −$17.1M | −$34.5M | −$26.6M | −$8.3M |
| Net income | −$11.2M | −$24.5M | −$11.9M | −$16.1M | −$26.6M | −$6.6M |
| Total assets | $18.3M | $22.6M | $11.9M | $14.5M | $49.6M | $33.4M |
| Total liabilities | $8.4M | $10.8M | $14.6M | $12.7M | $30.8M | $9.0M |
| Equity | $9.8M | $11.8M | −$2.8M | −$113,000 | $18.2M | $24.4M |
| EPS (diluted) | $-0.78 | $-15.65 | $-10.26 | $-3093.42 | $-4.19 | $-2.03 |
| Shares out. | 17.0M | 6.2M | 30.0M | 8.8M | 8.1M | 4.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −3939.1%
- Net margin
- −3509.7%
- Return on equity
- −114.3%
- Return on assets
- −61.5%
- Return on capital (ROCE)
- −128.3%
- Liabilities / assets
- 46.2%
- Debt / equity
- 0.86×
- Book value / share
- $0.58
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -23.25distress
- Accruals / assets
- 19.7%high accruals
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2022
- NT 10-Qmissed a reporting deadline ↗May 17, 2022
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Olmsted Investments LlcPassive (13G)Aug 29, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jensen ThomasOfficer — CEO | Jan 28, 2026 | Grant | 200,000 | $0.00 |
| Hoeiland JesperDirector | Jan 7, 2026 | Grant | 25,000 | $0.00 |
| Mclaughlin Gerald W.Director | Jan 28, 2026 | Grant | 45,000 | $0.00 |
| Ervin Jeffrey SOfficer — CFO | Jan 28, 2026 | Grant | 150,000 | $0.00 |
| Graff Jeremy R.Officer — See Remarks | Jan 7, 2026 | Grant | 133,333 | $0.00 |
| Graff Jeremy R.Officer — See Remarks | Sep 30, 2025 | Option exercise | 39,494 | — |
| Graff Jeremy R.Officer — CDO | Jan 22, 2025 | Grant | 144,441 | $0.00 |
| Epshinsky AlexanderOfficer — CFO | Jan 22, 2025 | Grant | 29,496 | $0.00 |
| Jensen ThomasOfficer — CEO | Jan 22, 2025 | Grant | 396,734 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 296,872 | 1.0 | +8.3% |
| Apr 30, 2026 | 274,063 | 2.1 | -8.2% |
| Apr 15, 2026 | 298,381 | 2.3 | -15.7% |
| Mar 31, 2026 | 353,879 | 3.1 | +22.3% |
| Mar 13, 2026 | 289,475 | 1.1 | +27.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventMay 8, 2026
- Other material eventMay 6, 2026
- Other material eventApr 28, 2026
- Other material eventApr 22, 2026
- Results of operationsApr 1, 2026
- Other material eventMar 9, 2026
- Entered a material agreement · New financial obligationMar 6, 2026
- Other material eventFeb 19, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-QMay 15, 2026
- 4OWNERSHIP DOCUMENTMay 14, 2026
- 4OWNERSHIP DOCUMENTMay 11, 2026
- 3May 11, 2026
- 8-KCURRENT REPORTMay 8, 2026
- 4OWNERSHIP DOCUMENTMay 7, 2026
- 8-KCURRENT REPORTMay 6, 2026
- ARSANNUAL REPORTApr 30, 2026
- DEFA14APROXY STATEMENTApr 30, 2026
- DEF 14APROXY STATEMENTApr 30, 2026
- 4/AOWNERSHIP DOCUMENTApr 30, 2026
- 4OWNERSHIP DOCUMENTApr 30, 2026
- 8-KCURRENT REPORTApr 28, 2026
- 424B3PROSPECTUSApr 27, 2026
- EFFECTApr 24, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.